Product Description
HLX6018 is Henlius’ self-developed novel anti-GARP/TGF-β1 mAb that binds to GARP/TGF-β1 complex and specifically blocks the release of GARP mediated TGF-β1, thus repressing the fibroblasts proliferation and ECM secretion caused by TGF-β1, and alleviating fibrosis symptoms. In preclinical studies, HLX6018 has demonstrated antifibrotic efficacy in both pulmonary and renal fibrosis models, and has a favorable safety profile. Afterwards, Henlius will continue to explore the efficacy of HLX6018 in a variety of fibrotic diseases including kidney fibrosis and liver fibrosis, steadily enrich the product’s indication layout in antifibrotic area. (Sourced from: https://www.henlius.com/en/NewsDetails-4510-26.html)
Mechanisms of Action: GARP Inhibitor,TGFB1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Henlius Biotech Co., Ltd./Shanghai Henlius Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Idiopathic Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20241106 | P1 |
Unknown |
Idiopathic Pulmonary Fibrosis |
None |